Pharmaceuticals News and Research

RSS

Pall inaugurates new Singapore Life Sciences Centre of Excellence

Pall Corporation, a global leader in filtration, separation and purification, today inaugurated its Pall Life Sciences Centre of Excellence in Singapore, the latest addition to the company's global customer support network.

From Pall Corporation 8 Sep 2011

Mass. Eye and Ear receives NIAID grant to coordinate Harvard-wide Project on Antibiotic Resistance

The Massachusetts Eye and Ear Infirmary has received an $11 million grant from the National Institute of Allergy and Infectious Disease, the largest National Institutes of Health grant in this hospital's187-year history, to coordinate the Harvard-wide Project on Antibiotic Resistance.

8 Sep 2011

First-ever comprehensive study of species origins of nature-derived drugs

In a first-ever comprehensive study of the species origins of nature-derived drugs, it is shown that drug-producing species are concentrated and clustered in a limited number of families, refuting the conventional view that as every nature species produces biologically active molecules, one can find drugs from almost any major block of species groups if one looks for them hard enough.

8 Sep 2011

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Teva Pharmaceutical Industries Ltd. and Alcobra Ltd. announced today top-line results from a six week, randomized, placebo-controlled, Phase II multi-center study designed to assess the safety and efficacy of MG01CI in adults with attention deficit hyperactivity disorder (ADHD).

7 Sep 2011

Simulations Plus preliminary fourth quarter revenues increase 6.9% to $1.426 million

Simulations Plus, Inc., a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its fourth fiscal quarter of fiscal year 2011, ended August 31, 2011 (4QFY11), and for the entire fiscal year 2011 (FY11).

7 Sep 2011

Hi-Tech Pharmacal first quarter sales increase 43% to $56.2 million

Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal first quarter ended July 31, 2011.

7 Sep 2011

First Edition: September 7, 2011

"Publicly, consumer and patient advocates continue to cheer wildly for last year's health care law. Behind the scenes, however, some worry that they are losing a few key battles to the insurance and business communities.

7 Sep 2011

Researchers rethink fenretinide for prevention of oral cancer

Scientists on the cutting edge of biomedical research know that research is a process - a combination of successes and failures that inform the next step forward. However, for some researchers at The Ohio State University progress means taking a step back. Supported by the Ohio State University Center for Clinical and Translational Science (CCTS), these scientists are using failed and forgotten research to uncover future treatments for major health conditions as diverse as oral cancer and stroke.

7 Sep 2011

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from a pilot clinical study to assess safety, tolerability, and multiple-dose pharmacokinetics of XIAFLEX (collagenase clostridium histolyticum) in adult Dupuytren's contracture subjects with multiple palpable cords.

7 Sep 2011

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.

7 Sep 2011

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Anacor Pharmaceuticals announced today that its partner, GlaxoSmithKline (GSK), has been awarded a contract with the U.S. Department of Health and Human Services' (HHS) Biomedical Advanced Research and Development Authority (BARDA) to support the ongoing development of GSK2251052 (GSK '052, formerly AN3665), a novel boron-based Gram-negative systemic antibiotic discovered by Anacor.

7 Sep 2011

Scientists uncover new ways to stimulate pancreatic beta cell growth

One of the holy grails in diabetes research is to discover molecules that stimulate beta cell growth and to find drugs that target these molecules. Now, JDRF-funded researchers in collaboration with the pharmaceutical company Hoffmann-La Roche, have done both, discovering not only a protein that regulates beta cell growth, but also a chemical compound that stimulates it.

7 Sep 2011

Drugs produced in offshore manufacturing plants more likely to have quality problems

Drugs produced in offshore manufacturing plants -- even those run by U.S. manufacturers -- pose a greater quality risk than those prepared in the mainland United States, a new study suggests.

7 Sep 2011

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

OncoGenex Pharmaceuticals, Inc. announced today that data from two studies, a Phase II clinical study and a pre-clinical study, evaluating the investigational compound custirsen, were published in the September issues of the journals Clinical Cancer Research and Cancer Research.

7 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced it has amended its agreement with Shiva Biomedical, LLC.

6 Sep 2011

ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that it has entered into agreements with Quintiles Commercial US, Inc. and Integrated Commercialization Services, Inc. (ICS) to support the anticipated launch of EXPAREL, should it be approved by the Food and Drug Administration (FDA) later this year.

6 Sep 2011

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

QIAGEN today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

From QIAGEN Manchester Limited 6 Sep 2011

Scale-up Systems establishes new office in India

Scale-up Systems Limited, the leading provider of process development software to the pharmaceutical industry, today announced it has established Scale-up Systems India Pvt. Ltd., a Mumbai-based subsidiary that will support its growing number of customers in India.

6 Sep 2011

Researchers discover novel way to increase amounts of antibiotics

A novel way of increasing the amounts of antibiotics produced by bacteria has been discovered that could markedly improve the yields of these important compounds in commercial production. It could also be valuable in helping to discover new compounds. With the ever-growing threat from antibiotic resistance, these tools will be very useful in ensuring that we have enough of these useful compounds in the future.

5 Sep 2011

Pharmaceuticals News and Research

Pall inaugurates new Singapore Life Sciences Centre of Excellence

Mass. Eye and Ear receives NIAID grant to coordinate Harvard-wide Project on Antibiotic Resistance

First-ever comprehensive study of species origins of nature-derived drugs

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Simulations Plus preliminary fourth quarter revenues increase 6.9% to $1.426 million

Hi-Tech Pharmacal first quarter sales increase 43% to $56.2 million

First Edition: September 7, 2011

Researchers rethink fenretinide for prevention of oral cancer

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

GSK receives HHS' BARDA contract to support development of Gram-negative antibiotic, GSK2251052

Scientists uncover new ways to stimulate pancreatic beta cell growth

Drugs produced in offshore manufacturing plants more likely to have quality problems

Leading cancer journals publish OncoGenex's custirsen pre-clinical and Phase II study data

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Shiva Biomedical, CorMedix to extend CRMD001 phase III trial in chronic kidney disease

ICS, Quintiles enter agreement with Pacira to support launch of EXPAREL

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

Scale-up Systems establishes new office in India

Researchers discover novel way to increase amounts of antibiotics

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence